Shelves normally destined for infant formula are nearly empty in a store in downtown Washington, DC on May 22, 2022.
Samuel Corum | AFP | Getty Images
Abbott Nutrition resumed infant formula production at its Sturgis, Michigan on Saturday, plans to move to address a shortage nationwide.
The company received the green light from the US Food and Drug Administration after meeting the “initial requirements” under a Consent decree May 16.
The company said it will restart production of EleCare, a formula for children who have difficulty digesting other products, along with other specialties and metabolic formulas.
Abbott is aiming for an initial EleCare product release around June 20 and is working to meet guidelines to resume production of Similac and other formulas.
“We understand the urgent need for a formula and our top priority is to bring a safe, high-quality formula into the hands of families across America,” a spokesperson for Abbott said in a statement. “We will increase production as quickly as possible, meeting all requirements.”
Although supply problems began at the start of the Covid-19 pandemic, the problems worsened in part due to the February closure of the Michigan plant while scrutinizing the contamination.
The FDA investigation began after four children were hospitalized with bacterial infections from drinking its powdered formula. Two of the children died.
“The FDA is continuing to work diligently to ensure the safe resumption of infant formula production at Abbott Nutrition’s Sturgis, Michigan facility,” the FDA said in a statement.
“The agency predicts that the steps and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan facility to safely resume production in the short term, will mean more and more infant formulas are on the way or already. on store shelves moving forward, “the FDA said.
Abbott Nutrition is the largest formula milk producer in the United States